Viscum album L. (European mistletoe), a member of the Santalaceae, is a hemiparasitic, evergreen shrub growing on deciduous and coniferous trees. In traditional and folk medicine, mistletoe was used for the treatment of central nervous system disorders such as epilepsy, hysteria, insomnia, nervous excitability, neuralgia, headache, dizziness and fatigue. However, relatively little is known of its neuropharmacological activity. The aim of the present study was to evaluate the effect of treatment with aqueous and hydroethanolic extracts from Viscum album L. parasitizing birch, linden and pine, on MAO-A and MAO-B activity as well as serotonin, dopamine and serotonin receptor 5-HTR1A levels in Galleria mellonella (Lepidoptera) larvae. The phytochemical composition of the extracts was characterised using UPLC-DAD-ESI-MS/MS. To investigate the neuropharmacological activity of Viscum album L. extracts, Galleria mellonella (Lepidoptera) larvae were used as a model organism. The inhibitory potential of the extracts against MAO-A and MAO-B was determined by fluorometry. The serotonin, dopamine and serotonin receptor 5-HTR1A levels in larvae hemolymph after treatment were quantified by ELISA. UPLC-DAD-ESI-MS/MS analysis allowed the identification of 88 compounds, either full or in part. Most of the characterised phytochemicals were flavonoids, hydroxycinnamic acids and lignans. Screening found that aqueous and hydroethanolic mistletoe extracts inhibited the enzymatic activity of either MAO-A or MAO-B or both. Additionally, mistletoe extract administration increased the levels of serotonin and serotonin receptor 5-HTR1A. None of the tested extracts had any significant effect on dopamine level. A key novel finding was that the aqueous and hydroethanolic extracts from Viscum album L. inhibited monoamine oxidase activity and increased the levels of serotonin and serotonin receptor 5-HTR1A in Galleria mellonella (Lepidoptera) larvae. These properties may be due to the presence of phenolic constituents, particularly flavonoids. Further research based on bioassay-guided fractionation of mistletoe is needed to identify CNS-active molecules.

Isothiocyanates (R-NCS) are sulphur-containing phytochemicals. The main source are plants of the Brassicaceae family. The best known plant-derived isothiocyanate is sulforaphane that has exhibited anticancer activity in both in vivo and in vitro studies. Recent attempts to expand their use in cancer therapy involve combining them with standard chemotherapeutics in order to increase their therapeutic efficacy. The aim of this paper is to determine the impact of sulforaphane and its natural analog alyssin on the anticancer activity of the well-known anticancer drug 5-fluorouracil. The type of drug-drug interactions was determined in prostate and colon cancer cell lines. Confocal microscopy, western blot and flow cytometry methods were employed to determine the mechanism of cytotoxic and cytostatic action of the combinations. The study revealed that additive or synergistic interactions were observed between 5-fluorouracil and both isothiocyanates, which enhanced the anticancer activity of 5-fluorouracil, particularly in colon cancer cell lines. An increased cytostatic effect was observed in case of alyssin while for sulforaphane the synergistic interaction with 5-fluorouracil involved an intensification of apoptotic cell death.

Valerian (Valeriana officinalis L.), passionflower (Passiflora incarnata L.), and ginkgo (Ginkgo biloba L.) are among the most widely used medicinal plants in European phytotherapy, with well-documented traditional use for anxiety, insomnia, cognitive decline, attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease. This narrative review critically analyses available clinical, pharmacological, toxicological, and regulatory data on these three species in the context of central nervous system (CNS) disorders. A comprehensive literature search was conducted in PubMed, Scopus, and the Cochrane Library; regulatory documents from the European Medicines Agency (EMA), the European Scientific Cooperative on Phytotherapy (ESCOP), and the World Health Organization (WHO) were also included. Valerian showed the most consistent clinical evidence for an improvement in sleep quality and reduction in anxiety. Passionflower demonstrated anxiolytic and mild sedative effects in several controlled trials. Ginkgo showed clinically relevant benefits in mild cognitive impairment, dementia, and vertigo. All three plants exhibited acceptable safety profiles at the recommended doses; however, significant drug interactions were identified, notably ginkgo’s inhibition of CYP2C19 and antiplatelet effects, and valerian’s potentiation of CNS depressants. Regulatory frameworks across EU member states remain inconsistent. Further high-quality randomized controlled trials with standardized extract characterization are needed.